Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport

Journal of Nuclear Medicine

Volumn 49, Issue 8, 2008, Pages 1386-1394

  Sharma, Rituka I ^a   Smith, Tim A D ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

18F FDG; Cetuximab; Colorectal; Glucose transport; Oncology; PET

Indexed keywords

ADENOSINE TRIPHOSPHATE; CETUXIMAB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GLUCOSE; HEXOKINASE; IRINOTECAN; LIPOCORTIN 5; OXALIPLATIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE REGULATION; CLONOGENIC ASSAY; COLORECTAL TUMOR; ENZYME ACTIVITY; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IC 50; INCUBATION TIME; MONOTHERAPY; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG INTERACTIONS; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; GLUCOSE; HEXOKINASE; HUMANS; ORGANOPLATINUM COMPOUNDS; RADIOPHARMACEUTICALS;

EID: 48749103295     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.047886     Document Type: Article

References (41)

1. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist. 2005;10:250-261.
2. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413-1418.
3. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5FU infusion +oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) [abstract]. Proc Am Soc Clin Oncol. 2002;21:129a.
4. Tournigand C, Andre T, Achhille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
5. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
6. van Cutsem E. Progress with biological agents in metastatic colorectal cancer leads to many challenges. J Clin Oncol. 2006;24:3325-3327.
7. Akhurst T, Kates TJ, Mazumdar M, et al. Recent chemotherapy reduces the sensitivity of [F-18]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol. 2005;23:8713-8716.
8. 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med. 2004;45:1480-1487.
9. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14:700-708.
10. Goshen E, Davidson T, Zwas ST, Aderka D. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat. 2006;5:37-43.
11. Flamen P. Positron emission tomography in colorectal cancer. Best Pract Res Clin Gastroent. 2002;16:237-251.
12. Bos R, van der Hoeven JJM, van der Wall E, et al. Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379-387.
13. Torizuka T, Zasadny KR, Recker B, Wahl RL. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology. 1998;207:767-774.
14. Minn H, Kangas L, Knuutila V, Paul R, Sipila H. Determination of 2-fluoro-2-deoxy-d-glucose uptake and ATP level for evaluating drug effects in neoplastic cells. Res Exp Med (Berl). 1991;191:27-35.
15. Balin-Gauthier D, Delord JP, Rochaix P, et al. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol. 2006;57:709-718.
16. Henriksson E, Kjellén E, Wahlberg P, Wennerberg J, Kjellström JH. Differences in estimates of cisplatin-induced cell kill in vitro between colorimetric and cell count/colony assays. In Vitro Cell Dev Biol Anim. 2006;42:320-323.
17. 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. J Nucl Med. 2006;47:1525-1530.
18. Miccoli L, Oudard S, Sureau F, Poirson F, Dutrillaux B, Poupon MF. Intracellular pH governs the subcellular distribution of hexokinase in a glioma cell line. Biochem J. 1996;313:957-962.
19. Boyer J, McLean EG, Aroori S, et al. Characterization of P53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res. 2004;10:2158-2167.
20. Sinha BK. Topoisomerase inhibitors: a review of their therapeutic potential in cancer. Drugs. 1995;49:11-19.
21. Voland C, Bord A, Péleraux A, et al. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther. 2006;5:2149-2157.
22. Gmeiner WH, Trump E, Wei C. Enhanced DNA-directed effects of FdUMP [10] compared to 5FU. Nucleosides Nucleotides Nucleic Acids. 2004;23:401-410.
23. Half E, Sun YJ, Sinicrope FA. Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells. Cancer Lett. 2007;251:237-246.
24. Xu H, Yu YJ, Marciniak D, et al. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther. 2005;4:435-442.
25. Raben D, Helfrich B, Chan DC, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res. 2005;11:795-805.
26. Smith TAD, Maisey NR, Titley JC, Jackson E, Leach MO, Ronen SM. Treatment of SW620 cells with tomudex and oxaliplatin induces changes in 2-deoxy-D-glucose incorporation associated with modifications in glucose transport. J Nucl Med. 2000;41:1753-1759.
27. Furuta M, Hasegawa M, Hayakawa K, et al. Rapid rise in FDG uptake in an irradiated human tumour xenograft. Eur J Nucl Med. 1997;24:435-438.
28. Pelicano H, Xu RH, Du M, et al. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol. 2006;175:913-923.
29. Boddie AW, Constantinou A, Williams C, Reed A. Nitrogen mustard upregulates Bcl-2 and GSH and increases NTP and PCr in HT-29 colon cancer cells. Br J Cancer. 1998;77:1395-1404.
30. Walenta S, Feigk B, Wachsmuth I, et al. Differential changes in purine nucleotides after doxorubicin treatment of human cancer cells in vitro. Int J Oncol. 2002;21:289-296.
31. Lutz NW. Contributions of metabol(om)ic NMR spectroscopy to the investigation of apoptosis. C R Chim. 2006;9:445-451.
32. Ferrari D, Stepczynska A, Los M, Sacbulze-Ostoff K, Wesselborg S. Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95- and anticancer drug-induced apoptosis. J Exp Med. 1998;188:979-984.
33. Azrak RG, Cao S, Slocum HK, et al. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res. 2004;10:1121-1129.
34. Motwani M, Sirotnak FM, She Y, Commes T, Schwartz GK. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res. 2002;62:3950-3955.
35. Krysko O, de Ridder L, Cornelissen M. Phosphatidylserine exposure during early primary necrosis (oncosis) in JB6 cells as evidenced by immunogold labelling technique. Apoptosis. 2004;9:495-500.
36. Lamb JR, Friend SH. Which guesstimate is the best guesstimate? Predicting chemotherapeutic outcomes. Nat Med. 1997;3:962-963.
37. Corsten MF, Hofstra L, Narula J, Reutelingsperger CPM. Counting heads in the war against cancer: defining the role of annexin A5 imaging in cancer treatment and surveillance. Cancer Res. 2006;66:1255-1260.
38. Smith TAD. The rate-limiting step for tumor [F-18] fluoro-2-deoxy-D- glucose (FDG) incorporation. Nucl Med Biol. 2001;28:1-4.
39. 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173-180.
40. Marom EM, Aloia TA, Moore MB, et al. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer. 2001;33:99-107.
41. Engles JM, Quarless SA, Mambo E, Ishimori T, Cho SY, Wahl RL. Stunning and its effect on H-3-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med. 2006;47:603-608.